Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator
Summary: Ivacaftor (VX-770) was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulatory drug approved for the treatment of patients with cystic fibrosis. Electron cryomicroscopy (cryo-EM) studies of detergent-solubilized CFTR indicated that VX-770 bound to a site at the inter...
Main Authors: | Onofrio Laselva, Zafar Qureshi, Zhi-Wei Zeng, Evgeniy V. Petrotchenko, Mohabir Ramjeesingh, C. Michael Hamilton, Ling-Jun Huan, Christoph H. Borchers, Régis Pomès, Robert Young, Christine E. Bear |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004221005101 |
Similar Items
-
Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
by: Stephanie Chin, et al.
Published: (2019-07-01) -
Non-canonical Shedding of TNFα by SPPL2a Is Determined by the Conformational Flexibility of Its Transmembrane Helix
by: Charlotte Spitz, et al.
Published: (2020-12-01) -
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
by: Rowe, Steven M., et al.
Published: (2017) -
Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
by: Argyri Petrocheilou, et al.
Published: (2020-01-01) -
Protocol for in vitro skin fibrosis model to screen the biological effects of antifibrotic compounds
by: Amir M. Alsharabasy, et al.
Published: (2021-03-01)